A Review of Empirical Evidence of Somatic Treatment Options for the MI/DD Population

A Review of Empirical Evidence of Somatic Treatment Options for the MI/DD Population This article reviews recent evidence in the literature for the use of psychotropic and other somatic treatments in the management of patients with mental retardation (MR). The search methodology included peer-reviewed English language publications in PubMed and PsychINFO with the words Mental Retardation, Intellectual Disability, Developmental Disability and Mental Disorders/Drug Therapy or Antipsychotic medications, Psychiatric Somatic therapies, Neuroleptic Drugs, Antidepressants and Electroconvulsive Therapy from 1998 to 2008. The review revealed few randomized controlled trials on the medications frequently prescribed for patients with MR. Three RCTs of Risperidone in children, one combining adults and children and one with adults only are discussed. There was one RCT involving Quetiapine and one on Citalopram. There is little evidence to support the scope of psychotropic medication use in the MR population though the field is advancing. The contribution of psychiatric illness to challenging behaviors is not systematically addressed in the literature. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Psychiatric Quarterly Springer Journals

A Review of Empirical Evidence of Somatic Treatment Options for the MI/DD Population

Loading next page...
Springer US
Copyright © 2008 by Springer Science+Business Media, LLC
Medicine & Public Health; Psychiatry; Public Health; Sociology, general
Publisher site
See Article on Publisher Site


  • Mental disorder in adults with intellectual disability. 1. Prevalence of functional psychiatric illness among a community-based population aged between 16–64 years
    Deb, S; Thomas, M; Bright, C
  • Longitudinal prescribing patterns for psychoactive medications in community-based individuals with developmental disabilities: Utilization of pharmacy records
    Lott, IT; McGregor, M; Engleman, L
  • Short and long term efficacy and safety of risperidone in adults with disruptive behavior disorders
    Gagiano, C; Read, S; Thorpe, L
  • The use of risperidone among individuals with mental retardation: Clinically supported or not?
    Singh, AN; Matson, JL; Cooper, CL
  • Cyclothymia or unstable mood disorder? A systematic treatment evaluation with valproic acid
    Verhoeven, WMA; Tuinier, S

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial